
- Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum.
- Shares are up 250% in the past year and just hit a new three-year high.
- ADPT maintains a 100% “Buy” opinion from Barchart, a Trend Seeker “Buy” signal, and robust technical indicators.
- Fundamentals show projected revenue and earnings growth, but the company struggles with profitability and exhibits high volatility.